Small Molecules Trigger Cofactor Shift to Regulate Hippo Pathway

Quick Summary

• The proceedings of the National Academy of Sciences (PNAS), Volume 122, Issue 27, July 2025, highlights TEAD proteins as transcriptional effectors of the Hippo pathway.
• These proteins are identified as promising targets for cancer therapy.
• Several drug-like TEAD inhibitors are under development with the objective to disrupt TEAD function and perhaps advance clinical treatments for certain cancers.

Read More

Indian Opinion Analysis
The research into TEAD protein inhibitors marks significant progress in cancer treatment development, offering potential breakthroughs against tumors influenced by the Hippo pathway.For India, which faces a rising burden of cancer cases annually, such advancements could eventually provide more effective therapies tailored to specific molecular pathways in patients. India’s burgeoning pharmaceutical industry might also find opportunities to engage actively in this domain-either through drug manufacturing or collaborations on similar therapeutic approaches for large-scale implementation domestically and globally.